Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies
Damiano Baroncini, Gıancarlo Comı(Casa di Cura Columbus), Angelo Ghezzi, Lucia Moiola(Vita-Salute San Raffaele University), Vittorio Martinelli(Vita-Salute San Raffaele University), B. Colombo(Université d'Évry Val-d'Essonne), G. Minonzio(Azienda Ospedaliera Sant’Antonio Abate di Gallarate), Pietro Annovazzi(Vita-Salute San Raffaele University), Mariaemma Rodegher(University of Milan), Mauro Zaffaroni(Associazione Italiana Sclerosi Multipla)
Cited by 68
Related Papers
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study
|The Lancet|2001|1.1k
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
|Multiple Sclerosis Journal|2018|706
Ofatumumab versus Teriflunomide in Multiple Sclerosis
|New England Journal of Medicine|2020|706